Regulation of HMG-CoA reductase

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Variability of total and pathogenic Vibrio parahaemolyticus densities in northern Gulf of Mexico water and oysters.

Applied and environmental microbiology·2007

Effect of intertidal exposure on Vibrio parahaemolyticus levels in Pacific Northwest oysters.

Journal of food protection·2004

Poly-L-glutamate, an anionic polymer, enhances transgene expression for plasmids delivered by intramuscular injection with in vivo electroporation.

Gene therapy·2002

Advances in plasmid gene delivery and expression in skeletal muscle.

Current opinion in molecular therapeutics·2001

Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma.

Human gene therapy·2000

Sphingolipids with inositolphosphate-containing head groups.

Advances in lipid research·1993

Neutral sphingomyelinase.

Advances in lipid research·1993

Ceramide: a novel second messenger.

Advances in lipid research·1993

Understanding barriers to effective malaria diagnosis and treatment: A mixed-methods study in Uganda, Nigeria, and Ivory Coast.

PLOS global public health·2026

Myocardial Infarction Without Obstructive Coronary Disease in Later Life: Insights from the Malmö Diet and Cancer Study.

Journal of clinical medicine·2026

Evidence-based insights into medial pedicle reduction mammaplasty: A systematic review and meta-analysis.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2026

EQ-5D Health Utility Gains with Once-Weekly Semaglutide 2.4 mg in People with MASH and F2/F3 Fibrosis: An Analysis of ESSENCE.

JHEP reports : innovation in hepatology·2026

Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography.

Hepatology communications·2026

Medicare Advantage and Type 2 Diabetes Outcomes.

JAMA internal medicine·2026

Related Experiment Videos

Regulation of HMG-CoA reductase

Related Concept Videos

First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.

Variability of total and pathogenic Vibrio parahaemolyticus densities in northern Gulf of Mexico water and oysters.

Effect of intertidal exposure on Vibrio parahaemolyticus levels in Pacific Northwest oysters.

Poly-L-glutamate, an anionic polymer, enhances transgene expression for plasmids delivered by intramuscular injection with in vivo electroporation.

Advances in plasmid gene delivery and expression in skeletal muscle.

Combination of interleukin 12 and interferon alpha gene therapy induces a synergistic antitumor response against colon and renal cell carcinoma.

Sphingolipids with inositolphosphate-containing head groups.

Neutral sphingomyelinase.

Ceramide: a novel second messenger.

Understanding barriers to effective malaria diagnosis and treatment: A mixed-methods study in Uganda, Nigeria, and Ivory Coast.

Myocardial Infarction Without Obstructive Coronary Disease in Later Life: Insights from the Malmö Diet and Cancer Study.

Evidence-based insights into medial pedicle reduction mammaplasty: A systematic review and meta-analysis.

EQ-5D Health Utility Gains with Once-Weekly Semaglutide 2.4 mg in People with MASH and F2/F3 Fibrosis: An Analysis of ESSENCE.

Simplified definition and imaging-based stratification of at-risk MASH using magnetic resonance elastography.

Medicare Advantage and Type 2 Diabetes Outcomes.

Related Experiment Videos

Regulation of HMG-CoA reductase

Related Concept Videos

Related Articles